Sinotau's Lutetium-177 trial in neuroendocrine tumors resumes recruiting
The Phase 2/3 China study raised its enrollment target to 85 and reopened recruitment, part of a radiopharmaceutical field that already includes multiple late-stage 177Lu-DOTATATE-class rivals.
Executive Summary
- A Phase 2/3 trial testing a radiolabeled somatostatin-receptor therapy in advanced neuroendocrine neoplasms returned to active recruitment after a period listed as not recruiting, with its enrollment target raised modestly.
- The shift lands within the range the operational model treats as routine, and it follows a sponsor track record of completing the large majority of its trials, so it reads as forward momentum rather than a setback.
- The therapy enters a somatostatin-receptor-targeted radiopharmaceutical field that already includes a commercially established comparator and several Phase 3 programs from other sponsors, meaning this readout will be judged against a mechanism class with prior human precedent rather than an untested one.
- The trial's primary completion date holds at mid-2027, and its outcome will test whether this specific radioligand, dosed in a broader neuroendocrine population than the classic well-differentiated tumor label, can reproduce the activity seen with related lutetium-177 therapies in the class.
The status change
The trial, registered as NCT06398444, moved from Active, not recruiting back to Recruiting on July 17, 2026, alongside an enrollment target increase from 74 to 85 patients. The study had briefly closed to enrollment on September 5, 2025, before this reversal reopened it roughly ten months later. The trial's primary completion date remains June 1, 2027, unchanged by this update. NCT06398444+1A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine NeoplasmsNCT06398444A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine NeoplasmsJul 17, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial tests
The study is a multicenter, single-arm, two-part design evaluating Lutetium Oxodotreotide in patients with inoperable, locally advanced or metastatic neuroendocrine neoplasms outside the classic well-differentiated gastroenteropancreatic tumor and neuroendocrine carcinoma categories, including grade 3 tumors, pheochromocytoma, and paraganglioma. Part 1 tracks the incidence and severity of adverse events through six months after the last dose, and Part 2's primary endpoint is overall response rate assessed by an independent review committee, tracked until disease progression or death over as long as five years. Enrollment requires confirmed somatostatin-receptor-positive disease by PET imaging and an ECOG performance status of 0 or 1. [177Lu, NCT06398444]
Sponsor execution
Sinotau Pharmaceutical Group has completed 7 of 8 prior trials in its portfolio, with 1 terminated, and runs a broader pipeline of 17 trials spanning Recruiting, Completed, and other statuses. The enrollment increase from 74 to 85 registers as a 0% jump against the operational model's routine threshold of plus-or-minus 20%, which the model does not flag as a concern. A single eligibility-criteria amendment and the enrollment-target adjustment together mark the only registry changes recorded since the trial's 2024 start. NCT06398444A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine NeoplasmsNCT06398444
The competitive field
The nearest modality precedent is Novartis's gallium-68 DOTA-TATE program in the same indication, a diagnostic imaging agent rather than a therapeutic comparator, according to the competitive landscape data. The broader SSTR2-targeted radiopharmaceutical class includes multiple Phase 3 programs testing lutetium-177 or actinium-225-labeled somatostatin analogs, including Jiangsu HengRui Medicine's lutetium-177 oxodotreotide program in gastrointestinal pancreatic neuroendocrine tumors and RayzeBio's actinium-225 dotatate program compared against standard of care in progressed gastroenteropancreatic neuroendocrine tumors. Sinotau itself runs a second Phase 3 trial of a differently formulated lutetium-177 oxodotreotide product in gastroenteropancreatic neuroendocrine tumors. Against this mechanism class, where lutetium-177-labeled somatostatin-receptor agents already carry regulatory and clinical precedent in related indications, the informative result for this trial is whether the response rate holds up in the broader, less-selected neuroendocrine neoplasm population it targets, a population that excludes the classic well-differentiated tumor label most prior approvals were built on.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.